Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA 7.5/650 vs CRYSTODIGIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium, which in turn promotes calcium influx via the Na+/Ca2+ exchanger, resulting in increased myocardial contractility (positive inotropy). It also has negative chronotropic and dromotropic effects via vagomimetic action.
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Treatment of heart failure with reduced ejection fraction (FDA-approved),Control of ventricular response in atrial fibrillation and atrial flutter (FDA-approved)
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
0.5 mg intravenously over 2-4 hours, then 0.25 mg every 6 hours as needed up to a total of 1.5 mg in 24 hours.
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Terminal elimination half-life approximately 1.6–1.9 days (38–45 hours) in patients with normal renal function; prolonged in renal impairment.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Primarily renal excretion; minimal hepatic metabolism. Not significantly metabolized by cytochrome P450 enzymes.
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Primarily renal excretion of unchanged drug; ~80-90% eliminated in urine, ~10-20% in feces via biliary excretion.
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
~20–25% bound to plasma proteins, primarily albumin.
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Vd approximately 5–10 L/kg, indicating extensive tissue distribution; clinical significance: large Vd means low plasma concentration relative to total body load, necessitating loading doses.
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
Oral: 60–80% (variable, depends on formulation and gastrointestinal factors); Intravenous: 100%.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
Cr Cl 10-50 m L/min: reduce dose by 25-50%; Cr Cl <10 m L/min: reduce dose by 50-75% or use alternative.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
Loading dose: 10-20 mcg/kg intravenously over 2-4 hours; maintenance: 5-10 mcg/kg every 6 hours as needed.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
Start at lower end of dosing range (0.25 mg intravenously), adjust based on renal function and response, monitor for toxicity.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
None.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Narrow therapeutic index; toxicity can be life-threatening.,Hypokalemia, hypomagnesemia, and hypercalcemia increase risk of digoxin toxicity.,Electrolyte monitoring and dose adjustment in renal impairment.,Patients with acute myocardial infarction, myocarditis, or severe pulmonary disease may be at increased risk of arrhythmias.
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
Ventricular fibrillation,Known hypersensitivity to digoxin or other digitalis glycosides,Hypercalcemia,Hypokalemia (uncorrected),Atrioventricular block (second- or third-degree) unless a pacemaker is present,Hypertrophic obstructive cardiomyopathy (relative contraindication)
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
Avoid high-fiber foods and large amounts of bran or pectin, as they may reduce absorption. Grapefruit juice may increase blood levels; limit consumption. Consistent dietary potassium intake is important; extremes (high or low) can affect drug action.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
Pregnancy Category C. First trimester: Association with fetal cardiac glycoside toxicity and malformations in animal studies; limited human data. Second trimester: Potential for fetal bradycardia and hypoxia due to placental transfer. Third trimester: Risk of neonatal digitalis toxicity, including arrhythmias and heart block.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
Excreted in breast milk in low concentrations (M/P ratio approximately 0.75-1.0). Considered compatible with breastfeeding; monitor infant for signs of toxicity (bradycardia, vomiting).
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
Increased volume of distribution and renal clearance in second and third trimesters may necessitate dose increases. Monitor serum digoxin levels and adjust to maintain therapeutic range (0.5-1.0 ng/m L).
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Crystodigin (digitoxin) has a very long half-life (~5-7 days) requiring careful monitoring to avoid accumulation. Unlike digoxin, it is primarily hepatically metabolized, so renal impairment has less impact on dosing. Always check for drug interactions with CYP3A4 inducers/inhibitors. Therapeutic monitoring of serum levels is essential (target 15-25 ng/m L).
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
Take exactly as prescribed; do not miss doses or double up.,Report any symptoms of toxicity: nausea, vomiting, visual disturbances (yellow-green halos), or irregular heartbeat.,Avoid over-the-counter medications without consulting your doctor, especially antacids and laxatives.,Keep regular appointments for blood tests to monitor drug levels and kidney function.,Do not stop suddenly; withdrawal can worsen heart condition.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA 7.5/650 vs CRYSTODIGIN, answered by our medical review team.
ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. CRYSTODIGIN is a Cardiac Glycoside that works by Cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium, which in turn promotes calcium influx via the Na+/Ca2+ exchanger, resulting in increased myocardial contractility (positive inotropy). It also has negative chronotropic and dromotropic effects via vagomimetic action.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA 7.5/650 and CRYSTODIGIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. The standard adult dose of CRYSTODIGIN is: 0.5 mg intravenously over 2-4 hours, then 0.25 mg every 6 hours as needed up to a total of 1.5 mg in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA 7.5/650 and CRYSTODIGIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . CRYSTODIGIN is classified as Category C. Pregnancy Category C. First trimester: Association with fetal cardiac glycoside toxicity and malformations in animal studies; limited human data. Second trimester: Potential for fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.